Topic
Shareholder Representation
Does Your M&A Deal Need a Professional Shareholder Representative?
Deal Terms Analysis, Indemnification
Deal Terms for M&A Escrows - Statistics and Key Findings
Deal Terms Analysis
Six Key Findings From the 2026 M&A Deal Terms Study
Deal Terms Analysis
2026 M&A Deal Terms Study
Due Diligence
2026 Best Practices in M&A Due Diligence
Deal Terms Analysis
Essential Purchase Price Adjustment Stats
Deal Terms Analysis
2026 Working Capital Purchase Price Adjustment Study
Tools for Practitioners
SRS Acquiom BarometerTM:
2026 M&A Outlook
Loan Agency
Europe’s Loan Market Eyes Emerging Markets and Regulation as Next Opportunities
Loan Agency
U.S. Credit Markets Outlook
Loan Agency
European Credit Markets Outlook
Deal Terms Analysis
M&A Deal Terms: Three Trends to Watch in 2026
Deal Terms Analysis, Life Sciences
2025 Life Sciences M&A Earnout Achievement: Key Findings by Industry Sector
Loan Agency
The ABCs of LMTs: Liability Management Transactions and What You Need to Know
Shareholder Representation
Expense Funds for the Win-Win
Deal Terms Analysis
2025 Update: M&A Undisclosed Liability Claims and Earnout Achievement
Deal Terms Analysis, Life Sciences
2025 SRS Acquiom Life Sciences M&A Study
Loan Agency
Credit Markets Outlook: Examining Trends in Private Credit and Broadly Syndicated Loans Across the U.S. and Europe
Shareholder Representation
M&A Tax: Key Considerations for Mergers & Acquisitions in 2025
Deal Terms Analysis
2025 M&A Deal Terms Special Report: Lower Middle-Market Deals
Indemnification
Why Are M&A Deal Parties Thinking Twice About RWI?
Loan Agency
2025 Insights from the Rise of Private Credit
Deal Terms Analysis, Indemnification
2025 Special Report: Influence of RWI on M&A Deal Terms
Due Diligence
Best Practices in M&A Due Diligence 2025